The stock should find initial resistance at its 50-day moving average ... respectively. Shares of Vivus (NASDAQ:VVUS) traded at a new 52-week low today of $1.90. This new low
Financial News Network Online · ByPeter Chu · 7/22/2015
Last month, VVUS shares sank sharply after the company’s stock rating was downgraded by Piper Jaffray. VVUS stock closed at $4.67 per share on Tuesday.
Investor Place · ByChristopher Freeburn · 5/28/2014
The stock market ended the Thursday session on a slightly higher ... CRAY, DLR, DTLK, EA, GMED, HK, VVUS, WAGE, ZLTQ, CHEF, ESS, GUID, QTM, SZYM, WBMD, GSIT, HNSN, ICFI, MOH, MTD, NGVC, OUTR, TEP, VTL, DECK, SB Other notable …
Briefing Live Market Analysis · 7/30/2015
Vivus Inc. (VVUS) stock is up over 18% today after the US Food and Drug Administration (FDA) approved its supplemental new drug application (sNDA) for Stendra. The drug was developed to treat erectile dysfunction (ED) and the recent approval allows for … · 9/19/2014
Many investors appear to be quite bearish on VIVUS, Inc. ( VVUS), especially if you look at the percentage of the float that is sold short for this stock. Currently, 35.97% of the float is sold short, suggesting an extreme level of bearishness for VVUS.
NASDAQ · 6/3/2014
Small cap obesity drug stock VIVUS, Inc (NASDAQ: VVUS), who’s potential obesity treatment peers include Arena Pharmaceuticals, Inc (NASDAQ: ARNA), EnteroMedics Inc (NASDAQ: ETRM) and Orexigen Therapeutics, Inc (NASDAQ: OREX), has …
Smallcap Network · 1/5/2015
Investors had high hopes for Arena's (NASDAQ: ARNA ) Belviq and VIVUS' (NASDAQ: VVUS ) Qsymia when ... to see whether either stock is worth buying. Past sales growth Arena is partnered with Eisai (NASDAQOTH: ESALY ) in marketing Belviq, and …
The Motley Fool · 5/31/2014
VIVUS Inc. (VVUS)’s monthly performance stands at -29.880% and VIVUS Inc. (VVUS) is considered a stock to watch with an analyst rating of 2.80 (Scale = 5 Strong Sell – 3 Neutral – 1 Strong Buy) Neuralstem, Inc. (CUR) of the Healthcare sector ... · 7/27/2015
Investor sentiment on Vivus (NASDAQ: VVUS) is low. The data seems to bear that out. Currently, 35.97 percent of the float on the stock is sold short, suggesting an extreme level of bearishness. A full 80 percent of the analyst’s ratings on Vivus are ...
Benzinga · 6/9/2014
More information on Sequenom and access to the free equity report can be found at: VIVUS, Inc. VVUS, -11.56% shares traded in the range of $12.33 to $13.07 Monday before settling to close at $12.41, a decrease of 1.35 percent. The stock appears to be ...
Market Watch · 7/2/2013
Related Searches